Hormonal Contraceptive Market to Reach $26.6 Billion, Globally By 2035 at 3.6% CAGR: Allied Market Research [Yahoo! Finance]
Teva Pharmaceutical Industries Limited American Depositary Shares (TEVA)
Last teva pharmaceutical industries limited american depositary shares earnings: 2/13 04:01 pm
Check Earnings Report
US:NYSE Investor Relations:
ir.tevapharm.com
Company Research
Source: Yahoo! Finance
WILMINGTON, Del. March 25, 2025 /PRNewswire/ -- Allied Market Research published a report, titled, Hormonal Contraceptive Market by Product (Oral Contraceptive Pills, Injectable Birth Control, Emergency Contraceptive Pills, Vaginal Rings, Transdermal Patches, IUS and Implants), Hormone (Progestin Only Contraceptive, Combined Hormonal Contraceptive), Age Group (15 to 24 Years, 25 to 34 Years, 35 to 44 Years, and Above 44 Years), and End User (Hospitals, Household, Clinics): Global Opportunity Analysis and Industry Forecast, 2024-2035" . According to the report, the hormonal contraceptive market was valued at $17.3 billion in 2023, and is estimated to reach $26.6 billion by 2035, growing at a CAGR of 3.6% from 2024 to 2035. In addition, government initiatives promoting contraception and rise in preference for long-acting reversible contraceptives contribute to market expansion. Request Sample of the Report on Global Hormonal Contraceptive Market 2035 - https://www.alliedmarketresea
Show less
Read more
Impact Snapshot
Event Time:
TEVA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TEVA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TEVA alerts
High impacting Teva Pharmaceutical Industries Limited American Depositary Shares news events
Weekly update
A roundup of the hottest topics
TEVA
News
- Teva Pharmaceutical Industries (NYSE:TEVA) had its price target raised by analysts at Piper Sandler from $30.00 to $40.00. They now have an "overweight" rating on the stock.MarketBeat
- Teva Pharmaceutical Industries' (NYSE:TEVA) investors will be pleased with their impressive 228% return over the last three years [Yahoo! Finance]Yahoo! Finance
- Teva Pharmaceutical Industries (NYSE:TEVA) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $31.00 to $35.00. They now have a "buy" rating on the stock.MarketBeat
- Alvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Biosimilar to Eylea®GlobeNewswire
- Teva Pharmaceutical Industries (NYSE:TEVA) had its price target raised by analysts at JPMorgan Chase & Co. from $28.00 to $35.00. They now have an "overweight" rating on the stock.MarketBeat
TEVA
Earnings
- 11/5/25 - Beat
TEVA
Sec Filings
- 12/18/25 - Form 4
- 12/18/25 - Form 4
- 12/12/25 - Form 144
- TEVA's page on the SEC website